Autoimmune Diseases
Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio
Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.
Nuvig Therapeutics Secures $161M Series B Funding for Autoimmune Therapy Development
Nuvig Therapeutics, autoimmune therapy, series B funding, Sanofi Ventures, autoimmune diseases, Fc gamma R2B, immunomodulatory therapy
Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases
Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.
Roche and COUR Pharmaceuticals Collaborate on Autoimmune Disease Treatment in Deal Worth Over $900 Million
Roche, COUR Pharmaceuticals, autoimmune disease, Genentech, antigen-specific immune tolerance platform, biotech collaboration
BMS’ CAR-T Therapy Shows Promising Results in Treating Lupus, Achieving Sustained Responses in Phase 1 Trial
CAR T therapy, Lupus treatment, Bristol Myers Squibb (BMS), Systemic lupus erythematosus (SLE), Autoimmune diseases, Cell therapy, Clinical trials
Nkarta Shifts Focus to Autoimmune Diseases, Deprioritizing Cancer Programs
Nkarta, autoimmune diseases, CAR NK cell therapy, NKX019, lupus nephritis, cancer programs, deprioritization
Jade Biosciences and Aerovate Therapeutics Announce Strategic Merger to Advance Autoimmune Disease Therapies
Reverse merger, Jade Biosciences, Aerovate Therapeutics, Paragon Therapeutics, Autoimmune diseases, JADE-001, IgA nephropathy (IgAN), Biotechnology
GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager
GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline
Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases